Cat. No.: HY-N0469

L-Lysine

9 Cited Publications

Avis client

Based on 9 publication(s) in Google Scholar

L-lysine is an essential amino acid for humans with orally activity. L-lysine can inhibit the occurrence of HSV infections and is used in herpes research. L-lysine increases calcium absorption, reduces diabetes-related diseases, improves gut health, and alleviates pancreatic inflammation. L-lysine can be used in research on metabolism, infection, and inflammation.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.94%
CAS No.: 56-87-1
Formule: C₆H₁₄N₂O₂
Masse moléculaire:146.19

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

L-Lysine Chemical Structure

CAS No.: 56-87-1

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vivo
Chemical Information
Publications (9)
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

IC₅₀ & Target

Microbial Metabolite

Human Endogenous Metabolite

Voir tous les produits spécifiques à Isoform Endogenous Metabolite :

Voir tous les produits spécifiques à Isoform HSV :

Voir tous les produits spécifiques à Isoform Ligands for E3 Ligase :

Cellular Effect

Cell Line	Type	Value	Description	References
HEK293	EC₅₀	158 μM Compound: 5962	Substrate uptake by the Cationic Amino Acid Transporter (CAT-3, SLC7A3) as assessed by the fluorescent FLIPR membrane potential dye in HEK-293 JumpIN-SLC7A3 cells Substrate uptake by the Cationic Amino Acid Transporter (CAT-3, SLC7A3) as assessed by the fluorescent FLIPR membrane potential dye in HEK-293 JumpIN-SLC7A3 cells	10.5281/zenodo.6782708
HEK293	EC₅₀	158 μM Compound: 5962	Substrate uptake by the Cationic Amino Acid Transporter (CAT-3, SLC7A3) as assessed by the fluorescent FLIPR membrane potential dye in HEK-293 JumpIN-SLC7A3 cells (PubChem AID: 1745863) Substrate uptake by the Cationic Amino Acid Transporter (CAT-3, SLC7A3) as assessed by the fluorescent FLIPR membrane potential dye in HEK-293 JumpIN-SLC7A3 cells (PubChem AID: 1745863)	10.5281/zenodo.6782708

In Vivo

L-lysine (5 or 10 mg/kg, p.o., single dose) ameliorates sepsis-induced acute lung injury in a lipopolysaccharide (HY-D1056)-induced mouse model^[3]. L-lysine (10 mg/kg, p.o., once daily for 45 days) treatment attenuates pancreatic tissue injury by inhibiting the release of the inflammatory cytokine IL-6, and enhances antioxidant activity in L-Arginine hydrochloride (HY-N0455A)-induced acute pancreatitis mice model^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

L-Arginine hydrochloride (HY-N0455A)-induced acute pancreatitis mice model^[4]
Dosage:

10 mg/kg
Administration:

Oral gavage (p.o.), single dose, pre-treated or post-treated
Result:

Led to significant decreases in the levels of malondialdehyde and nitric oxide, while significant enhancement was observed in the activities of antioxidant enzymes (superoxide dismutase, catalase, and glutathione peroxidase) and glutathione (p < 0.001).

Animal Model:

Lipopolysaccharide (HY-D1056) -induced mouse model^[4]
Dosage:

5 mg/kg, 10 mg/kg
Administration:

Oral gavage (p.o.), once daily for 45 days
Result:

Significantly reduced lipid peroxidation, total protein content, lung tissue wet/dry ratio, tumor necrosis factor-alpha, interleukin-8, and macrophage inhibitory factor levels, myeloperoxidase activity, as well as total cell, neutrophil, and lymphocyte counts.
Increased the levels of reduced glutathione and the activities of glutathione peroxidase, superoxide dismutase, and catalase.

Chemical Information

CAS No. 56-87-1
Appearance Solid
Masse moléculaire 146.19
Formule C₆H₁₄N₂O₂
Color Off-white to yellow
SMILES

N[C@@H](CCCCN)C(O)=O
Structure Classification
- Amino acids
Initial Source
- Microorganisms
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (9)

All In Vivo Efficacy StudyIFCell Migration/Invasion AssayWBMicrobiological Assay

Sort by:

Journal Impact Factor

Nature

Lithocholic acid phenocopies anti-ageing effects of calorie restriction. [Abstract]

2025 Jul;643(8070):192-200. PMID: 39695227
Microbiome

Species-specific enhancement of enterohemorrhagic E. coli pathogenesis mediated by microbiome metabolites. [Abstract]

2019 Mar 20;7(1):43. PMID: 30890187
Amino Acids

Identification of amino acids metabolomic profiling in human plasma distinguishes lupus nephritis from systemic lupus erythematosus. [Abstract]

2024 Sep 18;56(1):56. PMID: 39292313
Cell Biochem Biophys

FOXA1 Transcriptional Repression of PLSCR1 Inhibits Tongue Squamous Cell Carcinoma Progression. [Abstract]

2025 May 30. PMID: 40445264
Vet Microbiol

The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]

2026 May:316:110992. PMID: 41865607
J Anim Physiol Anim Nutr

Lysine stimulates the development of the murine mammary gland at puberty via PI3K/AKT/mTOR signalling axis. [Abstract]

2022 Nov;106(6):1420-1430. PMID: 35923149
iMetaOmics

2025 Aug 06.

L-Lysine purchased from MedChemExpress. Usage Cited in: iMetaOmics. 2025 Aug 06.

Serum FITC-dextran levels were reduced upon L-Lysine (200 mg/kg; once daily; i.g.; 7 d) supplementation, indicating improved barrier function. L-Lysine also partially reversed the weight loss.

L-Lysine purchased from MedChemExpress. Usage Cited in: iMetaOmics. 2025 Aug 06.

Representative immunofluorescence images of ZO-1 and red mean density analysis of ZO-1 in the ileum and colon. L-Lysine (200 mg/kg; once daily; i.g.; 7 d) supplementation significantly restored ZO-1 density.

L-Lysine purchased from MedChemExpress. Usage Cited in: iMetaOmics. 2025 Aug 06.

Effect of L-Lysine (1.4 mM; 12 h) intervention on the scratch injury healing rate of IFN-γ pre-processed and NCM-460 cells. IFN‐γ significantly impaired healing in NCM-460 cells, and this effect was significantly alleviated by L‐Lysine.

L-Lysine purchased from MedChemExpress. Usage Cited in: iMetaOmics. 2025 Aug 06.

Effects of L-Lysine (1.4 mM; 24 h) intervention on the ZO-1 and Occludin expression of IFN-γ pre-processed HIEC-6 cells by western blot.

L-Lysine purchased from MedChemExpress. Usage Cited in: iMetaOmics. 2025 Aug 06.

L-Lysine (0.7-2.8 mM) dose-dependently inhibits H.biformis growth in vitro.
Patent

US20240216332A1.
Laurea Magistrale in Biomedical Engineering, Politecnico di Milano

2019 Jun.

Solvant et solubilité

In Vitro:

H₂O : 100 mg/mL (684.04 mM; Need ultrasonic)

DMSO : < 1 mg/mL (insoluble or slightly soluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

6.8404 mL

34.2021 mL

68.4041 mL

5 mM

1.3681 mL

6.8404 mL

13.6808 mL

10 mM

0.6840 mL

3.4202 mL

6.8404 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: ≥ 100 mg/mL (684.04 mM); Clear solution

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (281 KB)
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Al-Malki AL. Suppression of acute pancreatitis by L-lysine in mice. BMC Complement Altern Med. 2015 Jun 23;15:193. [Content Brief]

[2]. Santos AMD, et al. Transitional metaplasia in intestinal epithelium of rats submitted to intestinal cystoplasty and treatment with L -lysine. Acta Cir Bras. 2017 Apr;32(4):297-306. [Content Brief]

[3]. Zhang Y, et al. L-lysine ameliorates sepsis-induced acute lung injury in a lipopolysaccharide-induced mouse model. Biomed Pharmacother. 2019 Oct;118:109307. [Content Brief]

[4]. Al-Malki AL. Suppression of acute pancreatitis by L-lysine in mice. BMC Complement Altern Med. 2015 Jun 23;15:193. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O	1 mM	6.8404 mL	34.2021 mL	68.4041 mL	171.0103 mL
	5 mM	1.3681 mL	6.8404 mL	13.6808 mL	34.2021 mL
	10 mM	0.6840 mL	3.4202 mL	6.8404 mL	17.1010 mL
	15 mM	0.4560 mL	2.2801 mL	4.5603 mL	11.4007 mL
	20 mM	0.3420 mL	1.7101 mL	3.4202 mL	8.5505 mL
	25 mM	0.2736 mL	1.3681 mL	2.7362 mL	6.8404 mL
	30 mM	0.2280 mL	1.1401 mL	2.2801 mL	5.7003 mL
	40 mM	0.1710 mL	0.8551 mL	1.7101 mL	4.2753 mL
	50 mM	0.1368 mL	0.6840 mL	1.3681 mL	3.4202 mL
	60 mM	0.1140 mL	0.5700 mL	1.1401 mL	2.8502 mL
	80 mM	0.0855 mL	0.4275 mL	0.8551 mL	2.1376 mL
	100 mM	0.0684 mL	0.3420 mL	0.6840 mL	1.7101 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

L-Lysine

9 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

L-Lysine

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Natural Product Library

FDA-Approved Drug Library

Antiviral Compound Library

Human Endogenous Metabolite Compound Library

Drug Repurposing Compound Library

Anti-diabetic Compound Library

Anti-COVID-19 Compound Library

Medicine Food Homology Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Gut Microbial Metabolite Library

Microbial Metabolite Library

Food Additive Library

Food-Sourced Compound Library

Inactive Ingredient Library

EMA-Approved Drug Library

Human Metabolite Library

Anti-Aging Natural Product Library

Off-patent Drug Library

Protease Inhibitor Library

Animal-Sourced Natural Product Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Dietary Supplement Library

RO5 Drug-like Natural Product Library

Flavor Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Endogenous Metabolite Library

Mass Spectrometry Human Metabolite Library

Mouse Metabolite Compound Library

Cosmetic Ingredient Compound Library

Amino Acid Metabolite Compound Library

20 Amino Acids Library

Mongolian Medicine Compound Library

Chinese Baijiu Compound Library

Flavors and Fragrances Compound Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

Mass Spectrometry Natural Product Library

Drug Fragment Library

Publications Citing Use of MedChemExpress (MCE) L-Lysine

Voir tous les produits spécifiques à Isoform Endogenous Metabolite

Voir tous les produits spécifiques à Isoform HSV

Voir tous les produits spécifiques à Isoform Ligands for E3 Ligase

Activité biologique

Chemical Information

Publications (9)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

L-Lysine Related Classifications

HY-N0469 Related Classifications